UK Exports to US Plunge 25 Following Trumps Liberation Day Tariffs Trade Deficit Emerges Analyst Coverage Initiated on Pinterest Inc as Market Evaluates Social Media Platforms Potential One House Three Owners How the American Dream of Homeownership Grows More Costly OpenAIs Potential IPO Valuation Trends and Key Risks to Watch Dow Jones Futures Edge Higher as SP 500 and Nasdaq Reach New Peaks AI Stocks in Focus JPMorgans Summer Reading List for the Affluent Highlights AI Leadership and Curious Lessons from Lemons Beneficient BENF Q1 2026 Earnings Stellar EPS Surprise Amid Revenue Discretion Highlights Financial Resilience Weyco Group Q1 2026 Earnings Steady EPS Performance Amid Challenging Retail Environment FSBW Q1 2026 Earnings Modest EPS Beat Highlights Stability Amid Soft Stock Response WAB Q1 2026 Earnings EPS Surpasses Estimates by Nearly 7 Stock Climbs Oxford Industries OXM Q1 2026 Earnings Significant EPS Miss but Shares Rally XOMA Royalty Corporation Q1 2026 Earnings EPS Misses Estimates Royalty Revenues Under Scrutiny Aprea Therapeutics APRE Edges Higher Amid Light Trading Key Resistance at 099 in Focus Oxford Square Capital Notes OXSQG Slides Slightly Amid FixedIncome Pressures WD40 Company WDFC Posts Measured Gain as Shares Approach Key Resistance Harvard Ave Acquisition Corp Rights HAVAR Gains on Low Volume Key Levels in Focus Lexicon Pharmaceuticals LXRX Slides 31 as Shares Test Key Support Levels Jamaica Weighs Oil Drilling Ambitions Against Green Commitments After Hydrocarbon Discovery GRWG Q1 2026 Earnings Narrower Loss Surprises Estimates Shares Edge Higher Argan Inc AGX Gains 383 Testing Resistance After Strong Momentum RRX Q1 2026 Earnings EPS Surpasses Estimates by 152 Shares Dip 262 CTKB Q1 2026 Earnings EPS Misses Estimates as Operating Losses Widen HIW Q1 2026 Earnings Massive EPS Surprise of 161 Drives Stock Rally CRVO Q1 2026 Earnings EPS Miss Reflects Continued Clinical Investment LMRI Q1 2026 Earnings EPS Surges Past Estimates Signaling Strong Operational Momentum AVR Q1 2026 Earnings Wider Than Expected Losses as PreRevenue Biotech Advances PRAX Q1 2026 Earnings EPS Beat Amid Continued RD Focus